Glenmark to Start Phase II Trials for Experimental Drug for Treating Crohn’s Disease

by Kathy Jones on  September 14, 2012 at 8:58 PM Clinical Trials News
RSS Email Print This Page Comment
Font : A-A+

Mumbai based drug maker Glenmark Pharmaceuticals revealed that it will starting the phase II clinical trials to test the effectiveness of its experimental drug for treating Crohn's disease and other inflammatory conditions in humans.
 Glenmark to Start Phase II Trials for Experimental Drug for Treating Crohn’s Disease
Glenmark to Start Phase II Trials for Experimental Drug for Treating Crohn’s Disease

The trials are being conducted in collaboration with Sanofi to test whether the drug, GBR 500, is effective in treating inflammatory conditions such as Crohn's disease, multiple sclerosis and ulcerative colitis.

The trials are being conducted at multiple clinical sites in North America and Europe by its subsidiary company Glenmark Pharmaceuticals SA.

Glenmark Pharmaceuticals Chief Scientific Officer Michael Buschle revealed that the phase II trials will be expanding the sample base to 100-300 people. "Despite treatment advances in recent years, UC remains a debilitating condition for many individuals, and represents an area of substantial unmet medical need", he said.



Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity Ulcerative Colitis Crohns Disease 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive